Tg Therapeutics (TGTX) Total Liabilities (2010 - 2026)
Tg Therapeutics (TGTX) posted quarterly Total Liabilities of $945.7 million for Q1 2026, up 125.49% year-over-year from $419.4 million in Q1 2025, and up 127.75% quarter-over-quarter from $415.2 million in Q4 2025.
Tg Therapeutics (TGTX) Total Liabilities (2010 - 2026) Analysis & Trends
Tg Therapeutics' Total Liabilities history runs 17 years deep, the most recent figure standing at $945.7 million for Q1 2026.
- In Q1 2026, Total Liabilities rose 125.49% year-over-year to $945.7 million; the TTM figure through Mar 2026 stood at $945.7 million (up 125.49% YoY), while the FY2025 annual figure was $415.2 million, up 16.86% from the prior year.
- Total Liabilities for Q1 2026 stood at $945.7 million, up from $415.2 million in the prior quarter.
- The five-year high for Total Liabilities was $945.7 million in Q1 2026, with the low at $117.4 million in Q3 2022.
- The 5-year median for Total Liabilities is $213.2 million (2024), against an average of $294.3 million.
- The sharpest annual moves came in 2022 and 2024: Total Liabilities dropped 5.26% in 2022, then surged 136.84% in 2024.
- Tg Therapeutics' Total Liabilities stood at $135.0 million in 2022, then climbed by 25.26% to $169.1 million in 2023, then jumped by 110.15% to $355.3 million in 2024, then rose by 16.86% to $415.2 million in 2025, then soared by 127.75% to $945.7 million in 2026.
- Business Quant data shows TGTX's Total Liabilities at $945.7 million in Q1 2026, $415.2 million in Q4 2025, and $417.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.62 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.72 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 4.00 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 7.02 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 10.03 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.35 Bn |
| 10 | Tg Therapeutics | 7.46 Bn | 6.78 Bn | 199.14 Mn | 1.04 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.04 Bn |
| Mar 31, 2026 | 945.71 Mn |
| Dec 31, 2025 | 415.23 Mn |
| Sep 30, 2025 | 417.81 Mn |
| Jun 30, 2025 | 426.18 Mn |
| Mar 31, 2025 | 419.40 Mn |
| Dec 31, 2024 | 355.33 Mn |
| Sep 30, 2024 | 393.86 Mn |
| Jun 30, 2024 | 223.64 Mn |
| Mar 31, 2024 | 213.21 Mn |
| Dec 31, 2023 | 169.09 Mn |
| Sep 30, 2023 | 166.30 Mn |
| Jun 30, 2023 | 180.40 Mn |
| Mar 31, 2023 | 169.93 Mn |
| Dec 31, 2022 | 134.99 Mn |
| Sep 30, 2022 | 117.41 Mn |
| Jun 30, 2022 | 122.63 Mn |
| Mar 31, 2022 | 132.64 Mn |
| Dec 31, 2021 | 142.48 Mn |
| Sep 30, 2021 | 98.17 Mn |